Clinical Trial

A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase 1 study of SBO-154 in patients with advanced cancers who are unable to tolerate or have not previously responded to standard therapy available in the country. The study involves multiple doses and takes place at several centers.
Protocol Amendment History 1 change
notable Trial sites expanded: 11 -> 15 locations 2026-05-16
Trial Details
NCT Number NCT07042100
Lead Sponsor Sun Pharma Advanced Research Company Limited
Conditions Advanced Solid Tumors
Enrollment 177 participants
Start Date 2025-08-12
Primary Completion 2028-08 (estimated)
Study Completion 2030-08 (estimated)
Updated on ClinicalTrials.gov 2026-07-28